First Look Analysts Research Calls for Thursday, January 5
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> Cullen/Frost (CFR) upgraded to Buy from Neutral at BofA Securities; tgt $155
> FibroGen (FGEN) upgraded to Buy from Neutral at BofA Securities; tgt raised to $27
> Interpublic (IPG) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $36
> Olin (OLN) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $65
> Group of America (RGA) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $167
Downgrades:
> Pearson Plc (PSO) downgraded to Underperform from Neutral at BofA Securities
> PNC (PNC) downgraded to Underperform from Neutral at BofA Securities; tgt raised to $160
> Prudential Plc (PUK) downgraded to Underperform from Neutral at Exane BNP Paribas
Others:
> Adaptimmune Therapeutics (ADAP) initiated with a Buy at EF Hutton; tgt $15
> Adaptive Biotechnologies (ADPT) initiated with a Sector Outperform at Scotiabank; tgt $15
> Allogene (ALLO) initiated with a Buy at EF Hutton; tgt $15
> Amylyx Pharmaceuticals (AMLX) initiated with a Buy at BofA Securities; tgt $50
> Atara Biotherapeutics (ATRA) initiated with a Buy at EF Hutton; tgt $25
> Bicycle Therapeutics (BCYC) initiated with a Buy at EF Hutton; tgt $55
> BioAtla (BCAB) initiated with a Buy at EF Hutton; tgt $25
> Bionano Genomics (BNGO) initiated with a Sector Outperform at Scotiabank; tgt $4
> Century Therapeutics (IPSC) initiated with a Buy at EF Hutton; tgt $18
> CRISPR Therapeutics (CRSP) initiated with a Buy at EF Hutton; tgt $75
> Fate Therapeutics (FATE) initiated with a Buy at EF Hutton; tgt $16
> G1 Therapeutics (GTHX) initiated with a Buy at EF Hutton; tgt $35
> Merus (MRUS) initiated with a Buy at EF Hutton; tgt $35
> Pacific Biosciences (PACB) initiated with a Sector Outperform at Scotiabank; tgt $12
> Rain Oncology (RAIN) initiated with a Buy at EF Hutton; tgt $16
> Replimune (REPL) initiated with a Buy at EF Hutton; tgt $60
> Twist Bioscience (TWST) initiated with a Sector Outperform at Scotiabank; tgt $33
> Veracyte (VCYT) initiated with a Sector Outperform at Scotiabank; tgt $33
Contact [email protected] for any questions or corrections.